drugset
drugset / Trial / NCT04011293

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

NCT04011293 ↗

Phase 0 Unknown 20 enrolled Shandong University Juventas Cell Therapy Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.

Timeline

Start
2019-07
Primary completion
2020-07
Completion
2022-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CNCT19 Cell therapy 500000 cells/kg Intravenous
Subject CNCT19 Cell therapy 4e+06 cells/kg Intravenous

Indications

refractory hematologic cancer